source
- Israeli biotech’s inhaled exosome therapy reduces respiratory failure in phase 2 studyNano24’s inhaled exosome therapy reduced respiratory failure in patients with acute respiratory distress syndrome (ARDS), hitting the main goal of a phase 2b study.Fierce Biotech · 1d ago↗ source
- Labcorp to acquire BioReference Health assets for $722M cashLabcorp and OPKO Health announced an agreement in which Labcorp will purchase select assets of BioReference Health, a subsidiary of OPKO. The assets include laboratory testing businesses focused o…